BMND7
MCID: BNM021
MIFTS: 15

Bone Mineral Density Quantitative Trait Locus 7 (BMND7)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 7

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 7:

Name: Bone Mineral Density Quantitative Trait Locus 7 57
Bmnd7 57

Classifications:



External Ids:

OMIM 57 611738

Summaries for Bone Mineral Density Quantitative Trait Locus 7

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 7, also known as bmnd7, is related to osteoporosis. An important gene associated with Bone Mineral Density Quantitative Trait Locus 7 is BMND7 (Bone Mineral Density Quantiative Trait Locus 7). The drugs Citalopram and Sertraline have been mentioned in the context of this disorder. Affiliated tissues include bone.

Description from OMIM: 611738

Related Diseases for Bone Mineral Density Quantitative Trait Locus 7

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 7

Clinical features from OMIM:

611738

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 7

Drugs for Bone Mineral Density Quantitative Trait Locus 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 3 59729-33-8 2771
2
Sertraline Approved Phase 3 79617-96-2 68617
3
Norepinephrine Approved Phase 3 51-41-2 439260
4
Reboxetine Approved, Experimental Phase 3 98769-81-4, 71620-89-8 123628 65856
5 Muscarinic Antagonists Phase 3
6 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
7 Cholinergic Agents Phase 3
8 Neurotransmitter Agents Phase 3
9 Neurotransmitter Uptake Inhibitors Phase 3
10 Antiparkinson Agents Phase 3
11 Antidepressive Agents, Second-Generation Phase 3
12 Psychotropic Drugs Phase 3
13 Autonomic Agents Phase 3
14 Cholinergic Antagonists Phase 3
15 Venlafaxine Hydrochloride Phase 3
16 Antidepressive Agents Phase 3
17 Serotonin Uptake Inhibitors Phase 3
18 Peripheral Nervous System Agents Phase 3
19 Adrenergic Agents Phase 3
20 Serotonin Agents Phase 3
21 Parasympatholytics Phase 3
22
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Antidepressants and Bone Mineral Density Completed NCT02179268 Phase 3 sertraline;citalopram;venlafaxine;reboxetine

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 7

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 7

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 7

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 7:

41
Bone

Publications for Bone Mineral Density Quantitative Trait Locus 7

Variations for Bone Mineral Density Quantitative Trait Locus 7

Expression for Bone Mineral Density Quantitative Trait Locus 7

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 7.

Pathways for Bone Mineral Density Quantitative Trait Locus 7

GO Terms for Bone Mineral Density Quantitative Trait Locus 7

Sources for Bone Mineral Density Quantitative Trait Locus 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....